Repotrectinib May Serve as a New Standard of Care Across Treatment Lines in ROS1+ NSCLC
Alexander Drilon, MD, highlights how the approval of repotrectinib addresses the need for improved therapies for patients who have progressed on a previous TKI and delves into notable neurologic toxicities seen with the agent.